ACB

Current Thesis

ACB is a sentiment-beta proxy on the U.S. cannabis-reschedule trade — but it's the wrong horse. Aurora is a Canadian LP with zero U.S. THC operations, so the actual economic catalyst (the April 24 2026 DOJ/DEA order moving FDA-approved + state-licensed medical product to Schedule III, killing 280E for U.S. medical operators) does not accrue to Aurora. ACB only catches the sector sentiment wave. Tape confirms it: stock sits at ~$3.46–3.59 (June 4), near the 52-week LOW of $3.07 vs a high of $6.67 — the April pop already faded. Two back-to-back binaries loom: Q4/FY26 earnings June 11 and the DEA broad-reschedule hearing June 29. This is a probe-only lottery ticket on a downtrend name, NOT the strength-is-the-setup momentum entry this book exists to catch.

Bull Case

• Medical-first pivot is actually working: medical net revenue $76.2M in Q3 FY26, +12% YoY, a record — 81% of consolidated net revenue, 95% of adjusted gross profit (per Q3 6-K). High-margin international medical (Germany, Poland, Australia, UK) is the real franchise, ~2.5x the margin of dead Canadian rec.
• Guidance raised toward profitability: FY26 global medical net revenue guided $269–281M (+10–15%), consolidated adjusted EBITDA $52–57M (+5–10% YoY) — a rare cash-generative, positive-EBITDA cannabis name.
• Squeeze optics: ACB is a perennial heavy-retail, low-dollar float. On any June 29 hearing headline that telegraphs a broad Schedule-I→III move, the whole complex (MSOS, TLRY, WEED) rips and ACB tags along violently on beta — historically +30–80% multi-day sympathy spikes.
• Net cash balance sheet (post years of dilution/asset sales) removes near-term solvency risk that haunts peers.

Bear Case

• The catalyst doesn't pay ACB. 280E relief and Schedule-III medical reclassification are U.S.-operator economics (GTBIF, CURLF, TCNNF, the MSOS ETF). A Canadian LP captures none of it. Buying ACB for the reschedule trade is buying the wrong ticker.
• Price structure is broken: ~$3.46 against a $3.07–6.67 52-wk range = sitting in the bottom decile, almost certainly below the 20/50/200-week MAs. This is value-trap, mean-reversion-down structure, not accelerating narrative.
• Recreational stays Schedule I (per the April 24 order); the June 29 hearing could expand scope but recreational reschedule is far from assured and faces challenge/appeal risk.
• Chronic dilution / reverse-split history — ACB has serially issued equity and reverse-split; any capital raise into a sentiment pop caps upside and re-punishes holders.
• Earnings binary in 5 trading days (June 11, pre-open) on a thesis that ISN'T earnings-driven = uncompensated risk for a fresh long today.

Setup & Price Structure

• Last ~$3.46–3.59 (May 31–Jun 4 2026); 52-wk range $3.07–$6.67. Trading ~48% off the high, ~15% off the absolute low.
• Near-lows position implies price is below 20-EMA / 50-DMA / 200-DMA — no momentum leg to buy; the cannabis-reclass theme has cooled from its April ACCELERATING burst to MATURING/rolling-over for Canadian LPs specifically.
• No clean higher-low base, no breakout retest. The only path to a tradable setup is an event-driven gap (earnings beat or hearing headline), i.e. binary, not structural.
• Beginner-trap matrix: NOT peak-retail-stretched (it's at lows), NOT extended above MA — but it IS earnings-in-<1-week and a textbook "was a good idea in April, is it still today?" trap. Do not average down a name sitting on its 52-wk low.

Catalyst Calendar (next 30 days)

• 2026-06-11 (pre-open) — Q4 & Full-Year FY2026 earnings call (CEO Martin / CFO King). Watch: medical rev vs $269–281M FY guide, adj-EBITDA vs $52–57M guide, FY27 outlook. BINARY, ~5 trading days out.
• 2026-06-29 (9am ET) — DEA expedited administrative hearing on broad Schedule-I→III rescheduling begins (concludes no later than 2026-07-15). Sector-wide sentiment driver; ACB participates only via beta. BINARY.
• 2026-04-24 (passed) — DOJ/DEA order placed FDA-approved + state-licensed medical product in Schedule III (context, already priced).

What Would Change Our Mind

• Upgrade to a real long: June 11 print beats the FY medical guide AND prints positive adjusted EBITDA at the high end, AND price reclaims the 50-DMA on volume — would convert this from lottery ticket to a momentum-base re-entry.
• June 29 hearing scope expands to recreational with credible timeline → sector-wide squeeze, ACB rides beta hard (probe could be added on confirmed breakout, not before).
• Kill it: weekly close below $3.07 (52-wk low) = confirmed broken structure; OR earnings miss vs the $269–281M / $52–57M guides; OR a dilutive equity raise announced.

Correlation Notes

• High beta to the U.S. cannabis complex: MSOS (AdvisorShares MSO ETF), TLRY, Canopy (WEED/CGC), and U.S. MSOs (GTBIF, CURLF, TCNNF). On reschedule headlines ACB moves with the group but lags on fundamentals since the catalyst is U.S.-operator-specific.
• Cleaner expressions of the actual June 29 reschedule trade are the U.S. MSOs / MSOS, not a Canadian LP — if we want the theme, prefer those; ACB only for a squeeze-beta probe.
• Low correlation to our AI/semis book — pure idiosyncratic regulatory/sentiment name; sizing it never competes with SUPREME conviction ideas there.

(Sources: Yahoo Finance / MarketBeat ACB quotes May 31–Jun 4 2026; Aurora Q3 FY26 6-K; Globe & Mail / StockTitan earnings-date release; DOJ/DEA April 24 2026 rescheduling order & Federal Register; Foley & Lardner / Holland & Knight reschedule analyses.)